{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T08:40:37Z","timestamp":1682325637721},"reference-count":36,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2002,7,1]],"date-time":"2002-07-01T00:00:00Z","timestamp":1025481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2002,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Highly specific borreliacidal antibodies are induced by infection with<jats:italic>Borrelia burgdorferi<\/jats:italic>, and a borreliacidal antibody test (BAT) may be an accurate laboratory procedure for confirming Lyme disease in clinical practice. To investigate this, 34 Lyme disease sera and 34 sera from patients with other illnesses who had presented to a primary-care facility located in an area of borreliosis endemicity were tested by the BAT and Western blotting (WB). The BAT was more sensitive (79% versus 65%;<jats:italic>P<\/jats:italic>= 0.090), especially in cases in which patients had a single erythema migrans lesion (<jats:italic>P<\/jats:italic>= 0.021). In addition, the potentially cross-reactive sera were negative by the BAT but WB yielded three (9%) false-positive results. The results from 104 sera from possible Lyme disease patients demonstrated the clinical usefulness of the more sensitive and specific BAT. The BAT was positive for 40 (38%) sera from patients with Lyme disease-related symptoms and appropriate clinical and epidemiological findings. WB confirmed Lyme disease in 30 (75%) of the 40 BAT-positive patients but failed to detect<jats:italic>B. burgdorferi<\/jats:italic>infection in 10 BAT-positive patients. WB was also positive for 11 BAT-negative sera, but six (55%) patients had case histories which suggested that the results were false positives. Collectively, the results confirm that the BAT is a sensitive and highly specific test and suggest that widespread use would increase the accuracy of serodiagnostic confirmation of Lyme disease.<\/jats:p>","DOI":"10.1128\/cdli.9.4.908-912.2002","type":"journal-article","created":{"date-parts":[[2002,7,28]],"date-time":"2002-07-28T23:07:23Z","timestamp":1027897643000},"page":"908-912","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":2,"title":["Ability of the Borreliacidal Antibody Test To Confirm Lyme Disease in Clinical Practice"],"prefix":"10.1128","volume":"9","author":[{"given":"Steven M.","family":"Callister","sequence":"first","affiliation":[{"name":"Microbiology Research Laboratory"},{"name":"Section of Infectious Diseases"},{"name":"Gundersen Lutheran Medical Foundation, Gundersen Lutheran Medical Center, La Crosse, Wisconsin 54601"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dean A.","family":"Jobe","sequence":"additional","affiliation":[{"name":"Microbiology Research Laboratory"},{"name":"Gundersen Lutheran Medical Foundation, Gundersen Lutheran Medical Center, La Crosse, Wisconsin 54601"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William A.","family":"Agger","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases"},{"name":"Gundersen Lutheran Medical Foundation, Gundersen Lutheran Medical Center, La Crosse, Wisconsin 54601"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald F.","family":"Schell","sequence":"additional","affiliation":[{"name":"Wisconsin State Laboratory of Hygiene"},{"name":"Department of Medical Microbiology and Immunology, University of Wisconsin, Madison, Wisconsin 53706"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd J.","family":"Kowalski","sequence":"additional","affiliation":[{"name":"Gundersen Lutheran Medical Foundation, Gundersen Lutheran Medical Center, La Crosse, Wisconsin 54601"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven D.","family":"Lovrich","sequence":"additional","affiliation":[{"name":"Microbiology Research Laboratory"},{"name":"Gundersen Lutheran Medical Foundation, Gundersen Lutheran Medical Center, La Crosse, Wisconsin 54601"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer A.","family":"Marks","sequence":"additional","affiliation":[{"name":"Microbiology Research Laboratory"},{"name":"Gundersen Lutheran Medical Foundation, Gundersen Lutheran Medical Center, La Crosse, Wisconsin 54601"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"510","DOI":"10.4065\/72.6.510","volume":"72","year":"1997","unstructured":"Agger, W. A., and K. L. Case. 1997. Clinical comparison of borreliacidal-antibody test with indirect immunofluorescence and enzyme-linked immunosorbent assays for diagnosis of Lyme disease. Mayo Clin. Proc.72:510-514.","journal-title":"Mayo Clin. Proc."},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/00005792-199103000-00001","volume":"70","year":"1991","unstructured":"Agger, W. A., K. L. Case, G. L. Bryant, and S. M. Callister. 1991. Lyme disease: clinical features, classification, and epidemiology in the upper Midwest. Medicine70:83-90.","journal-title":"Medicine"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.34.3.524-529.1996"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.62.11.4929-4937.1994"},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1093\/infdis\/175.2.466","volume":"175","year":"1997","unstructured":"Burkot, T. R., M. E. Schriefer, and S. A. Larsen. 1997. Cross-reactivity to Borrelia burgdorferi proteins in serum samples from residents of a tropical country nonendemic for Lyme disease. J. Infect. Dis.175:466-469.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0934-8840(98)80109-6","volume":"288","year":"1998","unstructured":"Cacciapuoti, B., S. Ciarrocchi, and L. Ciceroni. 1998. The complement-killing of Borrelia burgdorferi: target antigens and sensitizing antibodies. Zentralbl. Bakteriol.288:121-129.","journal-title":"Zentralbl. Bakteriol."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.26.12.2632-2636.1988"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.28.2.363-365.1990"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/cdli.3.4.399-402.1996"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/infdis\/167.1.158","volume":"167","year":"1993","unstructured":"Callister, S. M., R. F. Schell, K. L. Case, S. D. Lovrich, and S. P. Day. 1993. Characterization of the borreliacidal antibody response to Borrelia burgdorferi in humans: a serodiagnostic test. J. Infect. Dis.167:158-164.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1001\/archinte.1994.00420140095012","volume":"154","year":"1994","unstructured":"Callister, S. M., R. F. Schell, L. C. L. Lim, D. A. Jobe, K. L. Case, G. L. Bryant, and P. E. Molling. 1994. Detection of borreliacidal antibodies by flow cytometry: an accurate, highly specific serodiagnostic test for Lyme disease. Arch. Intern. Med.154:1625-1632.","journal-title":"Arch. Intern. Med."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.29.9.1773-1776.1991"},{"key":"e_1_3_2_14_2","first-page":"20","volume":"46","year":"1997","unstructured":"Centers for Disease Control and Prevention. 1997. Lyme disease. Morb. Mortal. Wkly. Rep.46:20-21.","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"e_1_3_2_15_2","first-page":"590","volume":"44","year":"1995","unstructured":"Centers for Disease Control and Prevention. 1995. Recommendations for test performance and interpretations from the Second National Conference on Serologic Diagnosis of Lyme Disease. Morb. Mortal. Wkly. Rep.44:590-591.","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"e_1_3_2_16_2","first-page":"126","volume":"21","year":"1994","unstructured":"Cooke, W. D., and N. H. Bartenhagen. 1994. Seroreactivity to Borrelia burgdorferi antigens in the absence of Lyme disease. J. Rheum.21:126-131.","journal-title":"J. Rheum."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.68.5.2647-2654.2000"},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1093\/infdis\/169.3.568","volume":"169","year":"1994","unstructured":"Fikrig, E., L. K. Bockenstedt, S. W. Barthold, M. Chen, H. Tao, P. Ali-Salaam, S. R. Telford, and R. A. Flavell. 1994. Sera from patients with chronic Lyme disease protect mice from Lyme borreliosis. J. Infect. Dis.169:568-574.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.66.5.2143-2153.1998"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1574-695X.2000.tb01499.x","volume":"29","year":"2000","unstructured":"Ikushima, M., M. Katsuhiko, F. Yamada, S. Kawahashi, and A. Nishikawa. 2000. Specific immune responses to a synthetic peptide derived from outer surface protein C of Borrelia burgdorferi predicts protective borreliacidal antibodies. FEMS Immunol. Med. Microbiol.29:15-21.","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/CDLI.6.6.930-933.1999"},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/infdis\/174.2.346","volume":"174","year":"1996","unstructured":"Johnson, B. J. B., K. E. Robbins, R. E. Bailey, B. L. Cao, S. L. Sviat, R. B. Craven, L. W. Mayer, and D. T. Dennis. 1996. Serodiagnosis of Lyme disease: accuracy of a two-step approach using a flagella-based ELISA and immunoblotting. J. Infect. Dis.174:346-353.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"3964","DOI":"10.4049\/jimmunol.146.11.3964","volume":"146","year":"1991","unstructured":"Kochi, S. K., R. C. Johnson, and A. P. Dalmasso. 1991. Complement-mediated killing of the Lyme disease spirochete Borrelia burgdorferi. Role of antibody in formation of an effective membrane attack complex. J. Immunol.146:3964-3970.","journal-title":"J. Immunol."},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.61.6.2532-2536.1993"},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1099\/0022-1317-49-10-917","volume":"49","year":"2000","unstructured":"Kraiczy, P., K. P. Hunfeld, S. Peters, R. Wurzner, G. Acker, B. Wilske, and V. Brade. 2000. Borreliacidal activity of early Lyme disease sera against complement-resistant Borrelia afzelii FEM1 wild-type and an OspC-lacking FEM1 variant. J. Med. Microbiol.49:917-928.","journal-title":"J. Med. Microbiol."},{"key":"e_1_3_2_26_2","first-page":"886","volume":"110","year":"1998","unstructured":"Kraiczy, P., S. Peters, C. Seitz, R. Wurzner, P. Oschmann, and V. Brade. 1998. Growth inhibitory and bactericidal efficacy of sera from Lyme borreliosis patients on B. burgdorferi strains. Wien. Klin. Wochenschr.110:886-893.","journal-title":"Wien. Klin. Wochenschr."},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.34.10.2343-2350.1996"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.63.6.2221-2227.1995"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.62.5.2079-2084.1994"},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1086\/314651","volume":"179","year":"1999","unstructured":"Porwancher, R. 1999. A reanalysis of IgM Western blot criteria for the diagnosis of early Lyme disease. J. Infect. Dis.179:1021-1024.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1086\/515382","volume":"178","year":"1998","unstructured":"Rousselle, J. C., S. M. Callister, R. F. Schell, S. D. Lovrich, D. A. Jobe, J. A. Marks, and C. A. Wieneke. 1998. Borreliacidal antibody production against outer surface protein C of Borrelia burgdorferi. J. Infect. Dis.178:733-741.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/167.1.165"},{"key":"e_1_3_2_33_2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1574-695X.1993.tb00383.x","volume":"7","year":"1993","unstructured":"Sambri, V., S. Armati, and R. Cevenini. 1993. Animal and human antibodies reactive with the outer surface protein A and B of Borrelia burgdorferi are borreliacidal, in vitro, in the presence of complement. FEMS Immunol. Med. Microbiol.7:67-72.","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"e_1_3_2_34_2","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1001\/archinte.1996.00440170121013","volume":"156","year":"1996","unstructured":"Sivak, S. L., M. E. Aguero-Rosenfeld, J. Nowakowski, R. B. Nadelman, and G. P. Wormser. 1996. Accuracy of IgM immunoblotting to confirm the clinical diagnosis of early Lyme disease. Arch. Intern. Med.156:2105-2109.","journal-title":"Arch. Intern. Med."},{"key":"e_1_3_2_35_2","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1086\/314663","volume":"179","year":"1999","unstructured":"Trevejo, R. T., P. J. Krause, V. K. Sikand, M. E. Schriefer, R. Ryan, T. Lepore, W. Porter, and D. T. Dennis. 1999. Evaluation of two-test serodiagnostic method for early Lyme disease in clinical practice. J. Infect. Dis.179:931-938.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_36_2","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.7326\/0003-4819-127-12-199712150-00011","volume":"127","year":"1997","unstructured":"Tugwell, P., D. T. Dennis, A. Weinstein, G. Wells, B. Shea, G. Nichol, R. Hayward, R. Lightfoot, P. Baker, and A. C. Steere. 1997. Laboratory evaluation in the diagnosis of Lyme disease. Ann. Intern. Med.127:1109-1123.","journal-title":"Ann. Intern. Med."},{"key":"e_1_3_2_37_2","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/ajcp\/107.2.142","volume":"107","year":"1997","unstructured":"Wormser, G. P., H. W. Horowitz, J. Nowakowski, D. McKenna, J. S. Dumler, S. Varde, I. Schwartz, C. Carbonaro, and M. Aguero-Rosenfeld. 1997. Positive Lyme disease serology in patients with clinical and laboratory evidence of human granulocytic ehrlichiosis. Am. J. Clin. Pathol.107:142-147.","journal-title":"Am. J. Clin. Pathol."}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CDLI.9.4.908-912.2002","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CDLI.9.4.908-912.2002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T08:13:04Z","timestamp":1682323984000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CDLI.9.4.908-912.2002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,7]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2002,7]]}},"alternative-id":["10.1128\/CDLI.9.4.908-912.2002"],"URL":"https:\/\/doi.org\/10.1128\/cdli.9.4.908-912.2002","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,7]]},"assertion":[{"value":"2002-01-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2002-03-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}